Comparative Efficacy of Super Bioavailable Itraconazole Capsules 50 mg vs 65 mg Twice Daily in the Management of Glabrous Tinea

Figures & data

Figure 1 Study design.

Abbreviation: *SB, Super-bioavailable itraconazole.

Table 1 Demographic Information of All Patients in Both the Groups

Parameters	SB 50 mg	SB 65 mg	p value
N	50	48
Male	28	25
Female	22	23
Age; mean (SD) Years	36.72 (12.16)	35.26 (11.14)	0.53
BMI; mean (SD)	24.52 (2.95)	24.68 (3.14)	0.45
Obese patients (BMI ≥25)	20	23
Duration of disease
<6 months; N	14	12
>6 months; N	36	36
Mean LSS (SD)	7.21 (2.04)	7.50 (1.90)	0.46
Mean ASS (SD)	2.81 (0.42)	2.92 (0.34)	0.15
Mean DLQI (SD)	13.43 (2.54)	13.64 (2.12)	0.65

Abbreviations: BMI, Body Mass Index; LSS, Lesion Severity Score; ASS, Area Severity Score; DLQI, Dermatology Life Quality Index.

Table 2 Complete Cure Rates in Different Dermatophytosis Groups

	SB 50 mg	SB 65 mg	p value
Complete population with dermatophytosis
N	50	48
Completely cured; N (%)	20 (40)	30 (62)	<0.05*
Relapse; N (%)	3 (15)	5 (17)	1
Recalcitrant dermatophytosis
N	36	36
Completely cured; N (%)	13 (36)	23 (64)	<0.05*
Relapse; N (%)	2 (15)	4 (17)	1

Note: *Statistically significant.

Table 3 Efficacy Scores in Terms of Mean LSS, ASS and DLQI at Week 6

Complete Population with Dermatophytosis
	SB 50 mg		SB 65 mg		p value*
N	50	CI	48	CI
Mean LSS (SD)	1.57 (1.22)	1.23–1.90	0.78 (0.82)	0.54–1.01	0.003
Mean ASS (SD)	0.76 (0.59)	0.59–0.92	0.46 (0.50)	0.32–0.60	0.008
Mean DLQI (SD)	2.91 (2.06)	2.34–3.48	1.67 (1.28)	1.30–2.03	0.0006
Recalcitrant dermatophytosis
	SB 50 mg		SB 65 mg		p value*
N	36	CI	36	CI
Mean LSS (SD)	2.33 (1.17)	2.00–2.65	0.76 (0.91)	0.50–1.01	0.0001
Mean ASS (SD)	1.11 (0.52)	0.96–1.25	0.42 (0.50)	0.28–0.56	0.0001
Mean DLQI (SD)	4.03 (1.89)	3.50–4.55	1.78 (1.35)	1.40–2.16	0.0001

Note: *Statistically significant.

Abbreviations: LSS, Lesion Severity Score; ASS, Area Severity Score; DLQI, Dermatology Life Quality Index; CI, Confidence Interval (95%).